Clinical Trial Detail

NCT ID NCT02420860
Title Study of Elotuzumab With Lenalidomide as Maintenance After Autologous Stem Cell Transplant (ASCT)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Boehringer Ingelheim
Indications

myeloid neoplasm

Therapies

Famotidine

Elotuzumab + Lenalidomide

Diphenhydramine

Dexamethasone

Age Groups: adult senior

No variant requirements are available.